Tenofovir

• Anti-HIV Agents
• Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
• ATC:J05AF07

• Chemet
• DMSA
• Mpi Dmsa Kidney Reagent

• Didrocal (Calcium Carbonate + Etidronate Disodium)

C₉H₁₄N₅O₄P

http://www.rxlist.com/cgi/generic/viread.htm

Tenofovir FDA

Tenofovir MSDS

No information avaliable

287.213 g/mol

276-280^oC

13.4 mg/mL in distilled water at 25°C (disoproxil fumarate salt)

Solid

0.01

Tablets for oral administration (300 mg)

For use, in combination with other antiretroviral agents, for the treatment of HIV-1 infection.

Tenofovir belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. Tenofovir is currently in late-stage clinical trials for the treatment of hepatitis B. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.

The oral bioavailability in fasted patients is approximately 25%. Administration of food (high fat meal containing 40 to 50% fat) increases the oral bioavailability, with an increase in the AUC of approximately 40%.

Limited clinical experience at doses higher than the therapeutic dose of tenofovir 300 mg is available. In Study 901 tenofovir disoproxil fumarate 600 mg was administered to 8 patients orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.

Human immunodeficiency virus